Adjustment of Dose & Administration
Indication-Specific Adjustment
- Treatment-naïve or treatment-experienced INSTI-naïve: 50 mg PO once daily
- Treatment-naïve/experienced INSTI-naïve when coadministered with UGT1A/CYP3A inducers (efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, or rifampin): 50 mg PO twice daily
- INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg PO twice daily
Renal Adjustment
No dose adjustments necessary; use caution in severe renal dysfunction for INSTI-experienced patients
Hepatic Adjustment
Use not recommended in patients with Child-Pugh C – have not been studied in this population
Drug-Specific Information
Dolutegravir is an integrase inhibitor (INSTI)
Restricted Use
ID consult is required for all HIV-positive inpatients receiving highly-active antiretroviral therapy (HAART). HAART medications may be dispensed prior to consult.
General Notes
- Up-to-date cost information, click here
- IV antimicrobials outpatient (OPAT) dosing, click here
- Obesity dosing weight recommendations here
- Helpful drug-drug interaction check website here
- When dosing guidance is provided it is important to note the following:
Fixed (ie non weight-based) doses in adults are historically based on a 70 kg patient. Specific disease states or individual patients may warrant dosages that differ from the above recommendations. Since product-specific criteria for dose adjustment based on creatinine clearance exist, consult product information regarding specific recommendations for dosage adjustment based on estimated creatinine clearance.